Skip to main content

Table 6 Diagnostic performance of Stathmin, Transgelin, BCOR and Cyclin-D1 expressions in differentiation between Leiomyosarcoma (LMS) and Endometrial stromal sarcoma (ESS)

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

MarkersTPFPTNFNSN % (95% CI)SP % (95% CI)PPV % (95% CI)NPV % (95% CI)Accuracy (95% CI)
Stathmin223190100%86.4% (72-100)88% (75.3-100)100%93.2% (85.()100)
Transgelin19022386.4% (72-100)100%100%88% (75.()100)93.2% (85.7-100)
BCOR19418386.4% (72-100)81.8% (65.7-100)82.6% (67.1-100)85.7% (70.7-100)84.1% (73.3-94.9)
Cyclin D1222200100%90.9% (78.()100)91.7% (80.()100)100%95.5% (89.()100)
Stathmin & Transgelin21121195.5% (86.()100)95.5% (86.()100)95.5% (86.()100)95.5% (86.()100)95.5% (89.()100)
Stathmin & BCOR223190100%86.4% (72-100)88% (75.()100)100%93.2% (85.()100)
Stathmin & Cyclin D1222200100%90.9% (78.()100)91.7% (80.()100)100%95.5% (89.()100)
Transgelin & BCOR20121290.9% (78.()100)95.5% (86.()100)95.2% (86.()100)91.3% (79.()100)93.2% (85.()100)
Transgelin & Cyclin D1221210100%95.5% (86.()100)95.7% (87.()100)100%97.7% (93.()100)
BCOR & Cyclin D120121290.9% (78.()100)95.5% (86.()100)95.2% (86.()100)91.3% (79.()100)93.2% (85.()100)
Stathmin, Transgelin & BCOR21121195.5% (86.()100)95.5% (86.()100)95.5% (86.()100)95.5% (86.()100)95.5% (89.()100)
Stathmin, Transgelin & Cyclin D1221210100%95.5% (86.()100)95.7% (87.()100)100%97.7% (93.()100)
Transgelin, BCOR & Cyclin D120022290.9% (78.()100)100%100%91.7% (80.()100)95.5% (89.()100)
Stathmin, BCOR & Cyclin D121022195.5% (86.()100)100%100%95.7% (87.()100)97.7% (93.()100)
Stathmin, Transgelin, BCOR & Cyclin D1220220100%100%100%100%100%
  1. TP True positive, FP False positive, TN True negative, FN False negative, SN Sensitivity, SP Specificity, PPV Positive Predictive Value, NPV Negative Predictive Value, 95%CI 95% Confidence Interval; p < 0.05 is significant